BioVersys AG, a clinical-stage biopharmaceutical company focused on novel antibacterial products for multi-drug resistant infections, announced that it will present new data on alpibectir together with its development partner GSK at The Union World Conference on Lung Health. The conference is scheduled for 17 to 20 November 2026 in Rio de Janeiro, Brazil, and brings together researchers, practitioners, advocates, policymakers and communities to accelerate progress in lung health.
The presentations will feature the latest Phase 2 data on alpibectir in combination with ethionamide (AlpE) in patients with newly diagnosed drug-sensitive pulmonary tuberculosis. The data are expected to provide critical insights into the early bactericidal activity, safety and pharmacokinetics of the AlpE combination, which is being developed to lower the efficacious human dose of ethionamide, minimize dose-dependent side effects and overcome ethionamide resistance.
The schedule includes an e-poster on Wednesday, 18 November, by Dr. Simphiwe RN Simelane titled “Early bactericidal activity, safety, and pharmacokinetics of alpibectir–ethionamide in pulmonary tuberculosis.” On Thursday, 19 November, Dr. Michel Pieren of BioVersys will present “Alpibectir potentiates ethionamide and ethionamide-sulfoxide activity in M. tuberculosis clinical isolates from a Phase 2a study,” followed by Dr. Simelane’s presentation of results from the ENABLE trial. On Friday, 20 November, Dr. Simon Tiberi will discuss early bactericidal activity, safety and pharmacokinetics of AlpE and updates on further development of alpibectir-containing TB regimens.
Alpibectir, previously known as BVL-GSK098, is a small molecule developed from BioVersys’ Transcriptional Regulatory Inhibitory Compounds (TRIC) platform in collaboration with GSK, the Institut Pasteur Lille and the University of Lille. It acts through a novel mode of action, potentiating ethionamide activity. The AlpE combination is being developed for pulmonary TB and TB meningitis. In 2023, AlpE received orphan-drug designation from the U.S. Food and Drug Administration, providing seven years of U.S. market exclusivity, and in 2025 it received Orphan Designation from the European Medicines Agency, providing 10-year EU market exclusivity.
The upcoming presentations are significant because tuberculosis remains a major global health threat, and new regimens that can improve efficacy while reducing side effects are urgently needed. The Phase 2 data could support further development of AlpE and potentially offer a new treatment option for patients with drug-sensitive TB. For BioVersys, the conference provides a platform to showcase its pipeline and collaboration with GSK, which may attract further investment and partnership opportunities. The original release is available on www.newmediawire.com, and more information about the company can be found at www.bioversys.com.
